Remicade and Conjunctivitis infective - a phase IV clinical study of FDA data

Summary:

Conjunctivitis infective is reported as a side effect among people who take Remicade (infliximab), especially for people who are female, 30-39 old, also take Mercaptopurine, and have Ankylosing spondylitis.

The phase IV clinical study analyzes which people have Conjunctivitis infective when taking Remicade. It is created by eHealthMe based on reports of 222,651 people who have side effects when taking Remicade from the FDA, and is updated regularly.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

What is Conjunctivitis infective?

Conjunctivitis infective (infection of the conjunctiva) is found to be associated with 81 drugs and 232 conditions by eHealthMe. Check the latest studies of Conjunctivitis infective.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

222,651 people reported to have side effects when taking Remicade.
Among them, 13 people (0.01%) have Conjunctivitis infective.

Could Remicade cause Conjunctivitis infective?

Among these 13 people:

What is the gender of people who have Conjunctivitis infective when taking Remicade? *

female: 91.67 %
male: 8.33 %

What is the age of people who have Conjunctivitis infective when taking Remicade? *

What are other drugs people take besides Remicade? *

What are other side effects people have besides Conjunctivitis infective? *

Chest Pain: 4 people, 30.77%
Blood Magnesium Decreased: 4 people, 30.77%
Hypotension (abnormally low blood pressure): 4 people, 30.77%
Dehydration (dryness resulting from the removal of water): 4 people, 30.77%
Dry Mouth: 3 people, 23.08%
Confusional State: 3 people, 23.08%
Oesophagitis (inflammation of oesophagus): 3 people, 23.08%
Neuritis (inflammation of nerve): 3 people, 23.08%
Cough: 3 people, 23.08%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 3 people, 23.08%

What are the existing conditions these people have? *

Stress And Anxiety: 2 people, 15.38%
Sleep Disorder: 2 people, 15.38%
Ankylosing Spondylitis (type of arthritis affecting the spine): 2 people, 15.38%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 7.69%
Joint Pain: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and have Conjunctivitis infective?

- Check whether Conjunctivitis infective is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remicade:

Remicade (224,011 reports)

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctivitis infective:

Conjunctivitis infective (81 drugs)

Browse all the conditions that are associated with Conjunctivitis infective:

Conjunctivitis infective (232 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab (the active ingredients of Remicade) and Remicade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.